Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
naizilai
- Development stage
- Unknown
- Lead developer
- Xinjiang Biomedicine Innovation and Research Center
- Administration
- Oral
01
Overview
Naizilai (乃孜来) is a traditional Uyghur medicine (TUM) developed as a granule formulation for the treatment of the common cold, specifically targeting the 'heat-type' (hot-type) naizilai syndrome according to Uyghur medical theory. It is being developed by the Xinjiang Institute of Ecology and Geography of the Chinese Academy of Sciences. The drug is currently in Phase III clinical trials in China to evaluate its efficacy and safety in improving recovery rates for common cold symptoms. As a botanical/herbal product, its mechanism likely involves multi-target anti-inflammatory and symptomatic relief properties characteristic of traditional herbal preparations.
- Other names
- naizilai granules乃孜来颗粒乃孜来
Beyond the preview
Go deeper on naizilai.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on naizilai.